Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-Derived Mesenchymal Stem Cell Conditioned Medium for Chronic Pain
jRCT1051250193Recruiting
- Sponsor
- Medical Clinic Ginza
- Start
- Dec 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ACT-20-CM in chronic pain, sponsored by Medical Clinic Ginza. Primary endpoints: Impact of pain on daily life, Pain pattern and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
ACT-20-CM
03
Conditions
chronic pain
Beyond the preview
Go deeper on jRCT1051250193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250193.